ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Stage- and Age-Specific Survival According to Histological Subtype in Renal Cell Carcinoma: A Nationwide Hospital-Based Cancer Registry Analysis in Japan.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo clarify stage- and age-specific overall survival (OS) according to histological subtype among surgically treated patients with RCC in Japan, we analyzed a nationwide hospital-based cancer registry.
methodsWe analyzed data from the Japanese nationwide hospital-based cancer registry and identified patients newly diagnosed with RCC between 2012 and 2014. Eligible patients underwent surgical treatment and had histologically confirmed clear cell, papillary, or chromophobe RCC with pathological stage (pStage) I-IV according to the UICC TNM classification, 7th edition. Patients treated with radiotherapy or local ablative therapies were excluded. OS was estimated using the Kaplan-Meier method and compared using the log-rank test.
resultsA total of 17 935 patients met the inclusion criteria, including 15 745 clear cell, 1340 papillary, and 850 chromophobe RCC cases. The 5-year OS rates for clear cell, papillary, and chromophobe RCC were 91.2%, 89.7%, and 93.5% at pStage I, and declined to 37.5%, 21.7%, and 59.3% at pStage IV, respectively. Age-stratified analyses in pStage I disease revealed progressively worse OS with advancing age across all histological subtypes. Among patients aged ≥ 85 years, the 5-year OS rates were 68.2% for clear cell, 50.0% for papillary, and 70.0% for chromophobe RCC.
conclusionsThis nationwide registry-based study provides updated real-world evidence on survival patterns in RCC in Japan. Advanced age was associated with reduced OS even in patients with pStage I disease, highlighting the importance of considering age when interpreting overall survival in surgically treated patients with RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.